[New guidelines for stage III melanoma (the French Cutaneous Oncology Group)]

B Guillot; A Dupuy; M Pracht; G Jeudy; E Hindie; E Desmedt; T Jouary; M-T Leccia

doi:10.1016/j.annder.2019.01.011

[New guidelines for stage III melanoma (the French Cutaneous Oncology Group)]

Ann Dermatol Venereol. 2019 Mar;146(3):204-214. doi: 10.1016/j.annder.2019.01.011. Epub 2019 Mar 2.

[Article in French]

Authors

B Guillot¹, A Dupuy², M Pracht³, G Jeudy⁴, E Hindie⁵, E Desmedt⁶, T Jouary⁷, M-T Leccia⁸

Affiliations

¹ Département de dermatologie, université de Montpellier, CHU de Montpellier, 34295 Montpellier, France. Electronic address: b-guillot@chu-montpellier.fr.
² Service de dermatologie, CHU de Rennes, 35033 Rennes, France.
³ Département d'oncologie médicale, centre Eugène-Marquis, 35000 Rennes, France.
⁴ Service de dermatologie, CHU de Dijon, Dijon, 21079 France.
⁵ Service de médecine nucléaire, CHU de Bordeaux, Bordeaux, 33076 France.
⁶ Service de dermatologie, CHU de Lille, 59037 Lille, France.
⁷ Service d'oncologie, centre hospitalier de Pau, 64000 Pau, France.
⁸ Service de dermatologie, CHU de Grenoble, 38043 Grenoble, France.

PMID: 30833037
DOI: 10.1016/j.annder.2019.01.011

Abstract

Improved knowledge of sentinel node procedures coupled with the results of adjuvant clinical trials in stage III melanoma have prompted the French Cutaneous Oncology Group to propose new guidelines for the management of stage III melanoma. These guidelines comply with the principles of the evidence-based medicine.

Keywords: Ganglion sentinelle; Guidelines; Immunotherapy; Immunothérapie; Mélanome stade III; Recommandations; Sentinel node; Stage III melanoma; Targeted therapy; Thérapie ciblée.

Publication types

Practice Guideline

MeSH terms

Humans
Melanoma / pathology*
Neoplasm Staging
Skin Neoplasms / pathology*